Therapeutic modalities directed at improving CD4 activation may prevent the initial loss of tolerance; however, CD8 specific therapies may be particularly advantageous in obviating the cell mediated destruction that characterizes diabetes progression. This evidence concerns the gene CD8A and diabetes mellitus.